Winway Health Desk
Illumina to acquire early cancer detection startup Grail for $8B
A startup focused on early detection of cancer that was spun out of one of the largest genetic analysis companies three years ago is...
AstraZeneca, Samsung reach $331M biologics manufacturing deal amid Korean CMO’s expansion...
Unlike some other manufacturers, Samsung Biologics has enjoyed a revenue boost from the novel coronavirus pandemic, and it's accelerating its expansion plans to match....
How COVID-19 Is Changing Behavioral Healthcare Facility Design
Mental and behavioral health are as vital to our collective well-being as our physical health. While the last decade has seen improved availability and...
The HCD 10: Lisa Lim, Educator
Who she is: Lisa Lim, PhD, began teaching while she pursued her doctorate at Georgia Institute of Technology, assisting Craig Zimring, director of SimTigrate...
MedCity Pivot Podcast: A conversation with AstraZeneca’s U.S. Head of Medical...
Lung cancer is the leading cause of cancer death among both men and women and accounts for about one-quarter of all cancer deaths in...
Bright Health raises $500M, plans expansion into employer-based insurance
Insurance startup Bright Health raised another $500 million, as it plans to expand into new markets and offer small group plans. The company, which...
Mayo’s Chief Digital Officer: The hospital of the future isn’t just...
Technologists conjure up images of the hospital of the future as a network of connected devices, automated systems and virtual visits. While all these...
How Covid-19 is driving regional innovation in digital health
Since the start of the Covid-19 pandemic, millions of people in every corner of the world have been touched by human tragedy and financial...
ESMO: Regeneron and Sanofi gun for Libtayo in first-line NSCLC with...
Regeneron and Sanofi made a splash back in April with data from a first-line study in non-small cell lung cancer (NSCLC) showing that their...
ESMO: Roche, after Tecentriq’s ovarian cancer fail, banks hopes on final...
Roche’s Tecentriq has chalked up a failure in ovarian cancer, leaving the disease still barren of a successful immunotherapy.
The addition of Tecentriq to Avastin...